The present invention relates to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac GTPases (Rac1, Rac1b, Rac2 and/or Rac3).
The invention concerns a thiazole of the formula I,
wherein Q¹ is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms;
X is oxy, thio, sulphinyl, sulphonyl or imino;
Ar is phenylene which may optionally bear one or two substituents, or Ar is an optionally substituted 6-membered heterocyclene moiety contining up to three nitrogen atoms;
R¹ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or substituted (1-4C)alkyl;
R² is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl or substituted (1-4C)alkyl or R² is optionally substituted benzoyl; and
Q² is optionally substituted thiazolyl;
or a pharmaceutically-acceptable salt thereof.
The invention also concerns processes for the manufacture of a thiazole of the formula I and pharmaceutical compositions containing said thiazole.
本发明涉及一种式 I 的噻唑、
其中 Q¹ 是任选取代的含有一个或两个氮原子的 6 元单环或 10 元双环杂环分子;
X 是氧基、硫代、亚砜基、磺酰基或亚氨基;
Ar 是亚苯基,可任选带有一个或两个取代基,或者 Ar 是任选被取代的 6 元杂环分子,含有最多三个氮原子;
R¹ 是氢、(1-6C)烷基、(2-6C)烯基、(2-6C)炔基或取代的(1-4C)烷基;
R² 是氢、(1-6C)烷基、(3-6C)烯基、(3-6C)炔基或取代的(1-4C)烷基,或 R² 是任选取代的苯甲酰基;以及
Q² 是任选取代的噻唑基;
或其药学上可接受的盐。
本发明还涉及式 I 噻唑的生产工艺和含有所述噻唑的药物组合物。